1. Home
  2. HQ vs MNPR Comparison

HQ vs MNPR Comparison

Compare HQ & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horizon Quantum Holdings Ltd. Class A Ordinary Shares

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$8.97

Market Cap

543.9M

Sector

N/A

ML Signal

N/A

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$68.97

Market Cap

587.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HQ
MNPR
Founded
2018
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
543.9M
587.4M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
HQ
MNPR
Price
$8.97
$68.97
Analyst Decision
Buy
Strong Buy
Analyst Count
2
12
Target Price
$18.50
★ $130.17
AVG Volume (30 Days)
96.5K
★ 127.0K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.99
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.29
$50.07
52 Week High
$45.00
$124.82

Technical Indicators

Market Signals
Indicator
HQ
MNPR
Relative Strength Index (RSI) 31.97 38.80
Support Level N/A $66.88
Resistance Level $13.90 $68.35
Average True Range (ATR) 1.28 4.54
MACD -0.33 0.51
Stochastic Oscillator 8.77 20.23

Price Performance

Historical Comparison
HQ
MNPR

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: